| Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 183.72 mm | 183.72 mm | 183.72 mm | 183.72 mm | 183.72 mm | 183.72 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 12.24 mm | 11.24 mm | 9.14 mm | 9.24 mm |
| Cash used (since last report) | n/a | n/a | 44.22 mm | 40.60 mm | 33.02 mm | 33.37 mm |
| Cash remaining | n/a | n/a | 139.50 mm | 143.12 mm | 150.70 mm | 150.35 mm |
| Runway (months of cash) | n/a | n/a | 11.4 | 12.7 | 16.5 | 16.3 |
| 13F holders | Current |
|---|---|
| Total holders | 96 |
| Opened positions | 17 |
| Closed positions | 16 |
| Increased positions | 31 |
| Reduced positions | 17 |
| 13F shares | Current |
|---|---|
| Total value | 125.97 bn |
| Total shares | 55.89 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Lynx1 Capital Management | 5.36 mm | $16.29 bn |
| Biotechnology Value Fund L P | 5.07 mm | $24.00 mm |
| EcoR1 Capital | 5.00 mm | $15.20 bn |
| BlackRock | 4.96 mm | $15.08 bn |
| K2 HealthVentures Equity Trust | 3.60 mm | $9.30 mm |
| Adage Capital Partners GP, L.L.C. | 3.50 mm | $10.64 bn |
| BVF | 2.99 mm | $9.09 bn |
| Baker Bros. Advisors | 2.78 mm | $8.47 bn |
| Vanguard | 2.38 mm | $7.24 bn |
| Propel Bio Management | 2.09 mm | $6.34 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Jan 25 | Jason Amello | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 3.065 | 270,000 | 827.55 k | 270,000 |
| 3 Jan 25 | Chrystal Louis | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 3.065 | 400,000 | 1.23 mm | 400,000 |
| 26 Dec 24 | Lynx1 Capital Management | Pre-funded Warrant Common Stock | Buy | Acquire P | Yes | No | 4 | 7,500,000 | 30.00 mm | 7,500,000 |
| 13 Dec 24 | Lynx1 Capital Management | Common Stock | Buy | Acquire P | Yes | No | 2.9014 | 100,000 | 290.14 k | 5,357,347 |
| 12 Dec 24 | Lynx1 Capital Management | Common stock, $0.0001 par value per share ("Common Stock") | Buy | Acquire P | Yes | No | 3.0072 | 31,800 | 95.63 k | 5,257,347 |
| 15 Nov 24 | Lynx1 Capital Management | Common stock, $0.0001 par value per share | Buy | Acquire P | Yes | No | 4.3442 | 947 | 4.11 k | 5,225,547 |
